Hemostemix Stock Price, News & Analysis

Hemostemix (OTCQB: HMTXF) has successfully closed a non-brokered private placement offering, raising CAD $469,366 through the issuance of 3,911,385 Common Shares at CAD $0.12 per share. The TSX Venture Exchange has granted conditional approval for this offering.

The funds will be directed towards general working capital, operational expenses, and business development activities. The issued securities are subject to a four-month hold period under Canadian securities laws. The investor is confirmed to be arm's length to the company and not a Related Party.

Hemostemix (OTCQB: HMTXF) has published its 10th scientific paper detailing ACP-01's molecular strategy for treating heart failure, specifically focusing on non-ischemic dilated cardiomyopathy (DCM). The publication highlights how ACP-01's unique characteristics differentiate it from traditional bone marrow-derived cell therapies.

The company's previous studies demonstrated that cardiac function improved by up to 47.1% after one ACP-01 treatment in DCM patients. ACP-01's effectiveness is attributed to three key mechanisms: precise migration to injured tissue through CXCR4 expression, attraction of Natural Killer cells to reduce inflammation and fibrosis, and improved microcirculation through angiogenesis.

Following Florida's new law permitting non-FDA approved stem cell treatments, Hemostemix is now offering ACP-01 therapy to no-option DCM patients in Florida.

Hemostemix (OTCQB:HMTXF) announced the appointment of Croom Lawrence as Chief Commercialization Officer. The company has partnered with Lawrence to offer MCI Screen, an FDA-approved and insurer-reimbursed advanced cognitive test for Vascular Dementia. The company noted that their ACP-01 treatment has shown clinical success in reversing vascular dementia in one patient for over ten years.

Hemostemix (OTCQB: HMTXF) announced a significant financial restructuring, with Chairman Peter Lacey providing a $1.5 million lead order for a non-brokered private placement at $0.10 per Unit. Each Unit includes one Common Share and one Warrant exercisable at $0.15 for two years. $1.25 million will be used to fully repay a $2.5 million Convertible Debenture.

The placement is part of a larger offering totaling up to $2.5 million. The company also confirmed the conversion price of previously announced ACP-01 Therapy Convertible Debentures (TCD) at CAD $0.155, relating to the March 5 sale of 15 TCDs for $708,605.

Hemostemix (HMTXF) has closed a non-brokered private placement raising CAD $469,366 through the issuance of 3,911,385 common shares at CAD $0.12 per share, pending TSXV Exchange approval. The securities will have a four-month hold period from closing. The proceeds will support general working capital, operational expenses, and business development. Hemostemix is an autologous stem cell therapy company that has developed ACP-01, a blood-based stem cell therapy. The company has completed seven clinical studies with 318 subjects, with results published in nine peer-reviewed publications. Their Phase II clinical trial for chronic limb threatening ischemia showed promising results, including 0% mortality and 83% wound healing in patients followed for up to 4.5 years.

Hemostemix Inc. (HMTXF) presented its clinical trial results at the TERMIS 2025 World Congress in Freiburg, Germany. The company showcased its Phase II clinical trial findings, published in JBRES, demonstrating significant improvements in ischemic tissue perfusion, pain reduction, wound healing, and limb salvage in no-option CLTI patients. The presentation also highlighted data from five heart studies investigating ACP-01 in various cardiac conditions.

CEO Thomas Smeenk emphasized the company's revenue generation of >$1 Million to date and discussed their strategy of using therapy convertible debentures sales to fund their phase III clinical trial. The company's autologous blood-based stem cell therapy, ACP-01, has completed seven clinical studies with 318 subjects, showing promising results for various cardiovascular conditions, with notably 0% mortality and 83% wound healing rates in CLTI patients.

Hemostemix (OTCQB: HMTXF) has completed a non-brokered private placement of USD $336,500, issuing 1,634,466 common shares at CAD $0.295 per share to CytoImmune Therapeutics LLC. The proceeds will be used for general working capital and business development activities.

The company is an autologous stem cell therapy platform developer that has completed seven clinical studies involving 318 subjects. Their lead product, ACP-01, has shown significant results in treating various conditions including peripheral arterial disease and chronic limb threatening ischemia (CLTI). Notable results from their Phase II CLTI trial showed 0% mortality and wound healing in 83% of patients, compared to the typical 60% five-year mortality rate.

[ "Successful completion of USD $336,500 private placement for working capital", "Strong clinical trial results with 0% mortality rate in CLTI patients vs. industry standard 60%", "83% success rate in wound healing for patients followed up to 4.5 years", "Extensive clinical experience with 7 completed studies involving 318 subjects" ]

Hemostemix Inc. (HMTXF) will participate in Invest Stuttgart 2025, Germany's leading finance and investment conference, from May 9-10, 2025. The company specializes in autologous stem cell therapies, with its flagship product ACP-01 treating various cardiovascular conditions. The therapy has demonstrated safety and efficacy across 498 patients and seven clinical studies.

The company has introduced ACP-01 Therapy Convertible Debentures (TCDs) as an innovative financing instrument, offering 6% annual interest payable in shares. TCDs can be converted into either ACP-01 therapy or common shares. Hemostemix has already sold over CAD $1.14 million of TCDs, supporting revenue forecasting and treatment scheduling.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) has partnered with PatentVest, a subsidiary of MDB Capital, to strengthen its global patent portfolio in autologous stem cell therapy for cardiovascular diseases. PatentVest will provide comprehensive IP support including:

• Evaluation and optimization of existing patents
• Identification of new patentable therapeutic innovations
• Development of global filing strategies
• Enhancement of company value for strategic partnerships

PatentVest will accept partial payment in equity, aligning with shareholder interests. The partnership aims to extend patent terms based on ongoing FDA studies and leverage the company's automated bioreactor technology license to reduce production costs and improve treatment accessibility.